Editing Antidepressant (section)

=== Bone loss ===
A 2021 nationwide [[cohort study]] in South Korea observed a link between SSRI use and bone loss, particularly in recent users. The study also stressed the need of further research to better understand these effects.<ref>{{cite journal|vauthors=Kang S, Han M, Park CI, Jung I, Kim EH, Boo YJ, Kang JI, Kim SJ|title=Use of serotonin reuptake inhibitors and risk of subsequent bone loss in a nationwide population-based cohort study|journal=Scientific Reports|volume=11|issue=1|pages=13461|date=June 2021|pmid=34188108|pmc=8241982|doi=10.1038/s41598-021-92821-9|bibcode=2021NatSR..1113461K}}</ref> A 2012 review found that SSRIs along with tricyclic antidepressants were associated with a significant increase in the risk of osteoporotic fractures, peaking in the months after initiation, and moving back towards baseline during the year after treatment was stopped. These effects exhibited a [[dose–response relationship]] within SSRIs which varied between different drugs of that class.<ref>{{cite journal|vauthors=Rizzoli R, Cooper C, Reginster JY, Abrahamsen B, Adachi JD, Brandi ML, Bruyère O, Compston J, Ducy P, Ferrari S, Harvey NC, Kanis JA, Karsenty G, Laslop A, Rabenda V, Vestergaard P|title=Antidepressant medications and osteoporosis|journal=Bone|volume=51|issue=3|pages=606–613|date=September 2012|pmid=22659406|doi=10.1016/j.bone.2012.05.018}}</ref> A 2018 meta-analysis of 11 small studies found a reduction in bone density of the lumbar spine in SSRI users which affected older people the most.<ref>{{cite journal|vauthors=Zhou C, Fang L, Chen Y, Zhong J, Wang H, Xie P|title=Effect of selective serotonin reuptake inhibitors on bone mineral density: a systematic review and meta-analysis|journal=Osteoporosis International|volume=29|issue=6|pages=1243–1251|date=June 2018|pmid=29435621|doi=10.1007/s00198-018-4413-0|s2cid=23313396}}</ref>